Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03050242
Other study ID # 2017-01-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date May 19, 2017

Study information

Verified date May 2018
Source Kangbuk Samsung Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is intended to evaluate the efficacy and safety of glycopyrrolate as an antisialagogue prior to intubation with the rigid-videostylet(Optiscope®) in the general anesthesia settings. Upper airway secretions limit the use of the videostylet during during endotracheal intubation. Therefore, in this study, patients will be allocated to either of the two groups according to the administration of glycopyrrolate and the effect of glycopyrrolate in reducing oral secretions will be assessed by the observer while intubating with the rigid-videostylet. The efficacy of the antisialagogic effect on the view during endotracheal intubation will be evaluated.


Description:

Recently, the newer forms of intubating devices combining video technologies were introduced. The fiberoptic stylets are useful instrumentations especially for difficult airways and limited neck mobilizations.The OptiScope® is a semi-rigid videostylet designed for endotracheal intubation. While using the device, visualization of the airway might be obscured by the secretions during its insertion. The deterioration of the view leads to intubation failure, resulting in multiple intubation attempts, longer intubating time and desaturation.Therefore, while using the Opticoscope®, proper antisialagogic preparation will be helpful.

Total 78 patients scheduled for general anesthesia aged 20-65 years and Anesthesiologists physical status (ASA) class 1 or 2 will be included. The obese patients (BMI>30) and expected difficult intubation will be excluded. The sample size was estimated based on the preliminary study. With a type Ⅰ error estimate(α) of 0.05 at 80% power, we estimated that 30 patients in each group, or 60 in total, were needed. Considering the drop-out rate of 30%, the total sample size were 78 in total. The patients will be randomly allocated to the glycopyrrolate group(G) and the control group(C). The group-G will received intramuscular glycopyrrolate 0.005mg/kg injection 1 hour before the surgery. For the group-C glycopyrrolate will not be administered. Intubation will be conducted with the OptiScope®. While intubating, the degree of the secretion will be evaluated through the OptiScope® and graded excellent, good, poor and unacceptable according to the dryness and the visualization of the vocal cord. When the vocal cord was seen without secretions, it was stated 'Excellent'. 'Good' was graded when secretions existed without the need for suctioning to visualize the vocal cord. When there were secretions and needed suctioning to clear the view, the subjects were rated 'Poor'. When intubation was failed due to poor visualization of the vocal cord despite the suctioning of the secretion, it was graded 'Unacceptable'. If the intubation is not available within 1 minute, the intubation will be done with the laryngoscope. The time to intubate will be checked by the assist anesthesiologist. The definition of the 'intubation time' is the time between the introduction of the OptiScope® into the mouth and the confirmation of the proper intubation with capnographic wave.The baseline vital signs including systolic blood pressure, mean arterial pressure, diastolic blood pressure and heart rate will be measured before the intubation and 1,3 and 5 minutes after the intubation.

The collected data will be compared with the independent t-test or Mann-Whitney-Wilcoxon test for the continuous variables. Χ2 test and Fisher's exact test will be performed for the categorical variables. Significant level will be set at 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date May 19, 2017
Est. primary completion date May 18, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients undergoing elective laparoscopic cholecystectomy under general anesthesia

- aged from 19 to 65, adult patients

- american society of anesthesiologist physical status 1,2

- obtaining written informed consent

Exclusion Criteria:

- obese patients with body mass index above 30

- expected difficult intubation (ex. intraoral mass, history of former difficult intubation, limitation of mouth opening..)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glycopyrrolate
Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery

Locations

Country Name City State
Korea, Republic of Kangbuk Samsung Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Eunah Cho, MD

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The degree of the secretion The degree of the secretion evaluation done through the OptiScope(R). It was graded by 4-point-scale. Excellent (1) : Dry. No secretion Good (2): Moist Acceptable (2): Wet. Suctioning is NOT required to intubate. Poor(4): Wet. Suctioning is required to intubate After an average of 1 second from the start of intubation with the OptiScope®.
Secondary Time to Intubate It is defined by the time between the introduction of the OptiScope® into the mouth and the confirmation of the proper intubation with capnographic wave. 2 minutes after the start of intubation with the OptiScope®.
See also
  Status Clinical Trial Phase
Completed NCT03767881 - AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE N/A
Recruiting NCT05975385 - Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy N/A
Completed NCT03470220 - The Role of Ultrasound in Cholecystitis
Recruiting NCT02972944 - Laparoscopic Cholecystectomy or Conservative Treatment in the Acute Cholecystitis of Elderly Patients N/A
Recruiting NCT05702775 - Endosonography-guided Gallbladder Drainage vs Non-endoscopic Treatment in Inoperable Acute Cholecystitis N/A
Recruiting NCT04542512 - Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.
Recruiting NCT04103762 - Interest of Intravenous Cholangiography With Indocyanine Green in the Context of Laparoscopic Cholecystectomy for Grade 1 and 2 Acute Gallstone Cholecystitis N/A
Completed NCT03014817 - Ultrasonically Activated Scalpel Versus Electrocautery Based Dissection in Acute Cholecystitis Trial N/A
Active, not recruiting NCT04612413 - A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients Phase 2
Withdrawn NCT04167072 - Observation vs Early Removal of LAMS in EUS Guided Cholecystoenterostomy N/A
Completed NCT04874103 - Hong Kong Follow up Protocol After EUS Gallbladder Drainage for Acute Cholecistitis
Completed NCT05041686 - Usefulness of the CADISS® System for the Cleavage of Severe Adhesions in Cholecystectomy N/A
Not yet recruiting NCT05339282 - Effectiveness of Empirical Antibiotic Use in Mild to Moderate Acute Inflammatory Gallbladder Disease N/A
Recruiting NCT06330688 - Prospective Evaluation of Ultrasound-guided Percutaneous Cholecystostomy With the Trocar Technique
Completed NCT02619149 - Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis Phase 3
Not yet recruiting NCT04661371 - Necessity of Preoperative Empirical Antibiotic Use in Acute Cholecystitis N/A
Completed NCT06178848 - EEG Parameters Between Remimazolam- and Propofol-based Anesthesia N/A
Completed NCT02394327 - Endoscopic Nasogallbladder Drainage Versus Gallbladder Stenting Before Cholecystecomy N/A
Completed NCT05179629 - M-Tapa Block for Laparoscopic Cholesistectomy N/A
Not yet recruiting NCT03021447 - Prediction of Postoperative Pain by Injection Pain of Propofol N/A